Peptinov is a biotechonology company based in Cochin Hospital (Paris, France) and founded by Prof. Jean-François Zagury to develop innovative peptide-based immunotherapies to treat chronic inflammatory diseases. Peptinov's strategy is to induce the production of antibodies targeting self-proteins directly by the organism of the patient, through immunizations against carefully selected, highly immunogenic peptide sequences. Peptinov's high potential R&D platform uses the tools of bioinformatics and molecular modelling to design these peptide sequences. This platform is potentially applicable to any crystallized protein and can quickly generate peptide candidates. Peptinov's value proposition is built on its unique capability to develop anti-self proteins products in the current pharmaceutical markets.Peptinov's most advanced product targets IL-6, a central pro-inflammatory cytokine involved in the pathogenesis of several diseases. Peptinov's anti-IL-6 immunotherapy is now in phase 1 clinical development.Video of Peptinov's approach: https://youtu.be/8j0GvgqPjxQ